Ashley Williams Haltom headshot

Atlanta, Georgia (December 11, 2020) – Georgia Bio, the state’s public policy and business solutions organization representing Georgia’s life sciences sector, announced an addition to its team hiring Ashley Williams Haltom as the Vice President of Government Affairs. In this role, she will provide expanded leadership in developing and implementing sound public policy strategies for Georgia Bio members and strengthen the voice of life sciences in the state.

“At this critical juncture, life sciences play a more prominent role than at any point in recent history. My top priority is to provide information and resources to policymakers on Georgia’s life sciences ecosystem and the important role that it plays in our state,” said Mrs. Haltom.

As Georgia’s biotechnology, medical device, agbio, and digital health communities continue to grow, the addition of Mrs. Haltom bolsters the organization’s government relations activities. Those activities seek to drive solution-oriented public policies and advocacy that support life sciences research, investment and innovation in the state.

Mrs. Haltom has almost a decade of experience working in politics and government, serving in roles with then-Governor Deal’s Office of Workforce Development, the Georgia House of Representatives, and state and federal campaigns. Most recently, she served as the Communications Director and Staff Lobbyist for a statewide trade association. She is a graduate of the University of Georgia with a degree in International Affairs.

“This role, with ongoing support from our lobbyist Cornerstone Government Affairs, will deepen our relationship with policymakers,” said Maria Thacker Goethe, Georgia Bio’s president and CEO. “Ashley will enhance awareness at the state level for the contributions our life sciences sector and member companies make to Georgia’s economy and improvements in patient care. I am delighted to welcome her to Georgia Bio.”

About Georgia Bio

Georgia Bio ( www.gabio.org ) is the state’s private, non-profit life sciences association. Members include pharmaceutical, biotechnology and medical device companies, medical centers, universities and research institutes, government groups and other business organizations involved in the development of life sciences related products and services.

Media Contact:
Kristina Forbes
404-920-2043
kforbes@gabio.org

Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community

By Sheran Brown • February 21, 2025
Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community

Bipartisan PBM Reform Back in Focus as House Committee Plans Hearing

By Sheran Brown • February 20, 2025
A renewed push for prescription drug cost reform is gaining momentum in Congress, with the House Energy and Commerce Committee's health subcommittee planning a hearing on pharmacy benefit manager (PBM) reform for late February. The hearing, to be led by Rep. Buddy Carter (R-Ga.), signals a revival of bipartisan efforts to regulate these pharmaceutical intermediaries. PBMs, which negotiate drug prices for insurers and employers, have become a focal point in the broader discussion of healthcare costs. A previous bipartisan agreement to regulate these entities was crafted by Carter and Rep. Diana DeGette (D-Colo.) in the last Congress, though it ultimately stalled when the larger spending bill it was attached to faced opposition. The reform efforts enjoy broad support from both parties and the president, making it one of the few areas with potential for bipartisan cooperation. However, new complications have emerged as Republicans consider using PBM regulations to generate savings for their broader policy agenda, potentially requiring up to $880 billion in cost reductions. The path forward remains uncertain, with ongoing debates about whether such reforms would qualify for budget reconciliation and whether using PBM regulations as a funding mechanism could derail bipartisan cooperation. Meanwhile, stakeholders continue to disagree on the impact of additional PBM regulation, with pharmaceutical companies arguing that PBMs inflate drug costs while PBMs contend that new regulations would increase prices.

Council on State Biotechnology Associations says NIH funds are a critical component of innovation ecosystem

By Sheran Brown • February 20, 2025
The Council of State Biotechnology Associations (CSBA) has issued a strong warning about proposed cuts to National Institutes of Health (NIH) funding, emphasizing the critical role these grants play in America's biotech innovation ecosystem. The statement, below , comes amid concerns over recent guidance that would reduce NIH funding to key research institutions. ----------------------- “Today, the US biotech industry employs nearly 2.3 million people across the US and is making positive contributions to economic impact and national security across all 50 states. In fact, for every dollar the National Institutes of Health (NIH) contributes to a successful drug, the private sector invests over $65, underscoring the agency’s unparalleled return on investment. As the associations representing the bioscience industry across the nation, the Council on State Biotechnology Associations (CSBA) is concerned by recent guidance that would cut funding provided by the NIH to universities, hospitals, and other institutions that perform critical early-stage research. NIH grant funds are a critical component of our innovation ecosystem. Grants for basic research are the spark that leads to university-driven discoveries, with public-private partnerships and tech transfers that bridge early-stage research to industry-sponsored drug development and ultimately to FDA approved medical advances for hundreds of diseases. While the administration looks for greater efficiency in the use of taxpayer dollars, it cannot be overstated - once scientific innovation moves abroad, it may never return. In the race for scientific innovation around the world, as our adversaries continue to increase government investments in research, we encourage President Trump to follow suit and ensure that we maintain our global leadership in an industry that was created and thrives across the US.”
MORE POSTS
Share by: